Live Oak Private Wealth LLC Reduces Holdings in Eli Lilly and Company $LLY

Live Oak Private Wealth LLC trimmed its position in shares of Eli Lilly and Company (NYSE:LLY) by 27.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,958 shares of the company’s stock after selling 747 shares during the quarter. Live Oak Private Wealth LLC’s holdings in Eli Lilly and Company were worth $1,526,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares in the last quarter. Covestor Ltd grew its holdings in Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after buying an additional 85 shares in the last quarter. Kaufman Rossin Wealth LLC purchased a new stake in Eli Lilly and Company in the 1st quarter valued at $242,000. Finally, Golden State Wealth Management LLC grew its holdings in Eli Lilly and Company by 9.1% in the 1st quarter. Golden State Wealth Management LLC now owns 1,019 shares of the company’s stock valued at $842,000 after buying an additional 85 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $810.78 on Thursday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The business’s fifty day simple moving average is $775.02 and its 200-day simple moving average is $770.34. The firm has a market cap of $767.37 billion, a PE ratio of 52.99, a price-to-earnings-growth ratio of 1.22 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the company earned $3.92 EPS. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Analysts Set New Price Targets

Several analysts have issued reports on LLY shares. UBS Group dropped their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a report on Friday, August 8th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. JPMorgan Chase & Co. decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. Finally, Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research note on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

Insider Activity

In other news, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 4,514 shares of company stock worth $2,894,841 in the last quarter. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.